目的 探讨金振口服液联合哌拉西林钠他唑巴坦钠治疗儿童社区获得性肺炎的临床疗效。方法 选取2022年1月—2024年11月在中山市小榄人民医院接受治疗的86例社区获得性肺炎患儿，按随机数字表法将患儿分为对照组和治疗组，每组各43例。对照组患儿采用注射用哌拉西林钠他唑巴坦钠，2.25 g/次，用稀释液充分溶解后加入100 mL注射液中静脉滴注，≥30 min/次，3次/d。治疗组在对照组治疗基础上口服金振口服液，5 mL/次，3次/d。两组疗程均为7 d。观察两组临床疗效和相关症状改善时间，比较治疗前后血气指标[动脉血氧分压（pO₂）、动脉血二氧化碳分压（pCO₂）]和炎症标志物[C反应蛋白（CRP）、中性粒细胞与淋巴细胞比值（NLR）、嗜酸性粒细胞（EOS）计数、血清降钙素原（PCT）]水平。结果 治疗后，治疗组总有效率是97.67%，显著高于对照组的86.05%（P＜0.05）。治疗后，治疗组喘促、咳嗽、发热、痰鸣、肺部啰音的改善时间均显著短于对照组（P＜0.05）。治疗后，两组pO₂显著升高，而pCO₂均显著降低（P＜0.05）；治疗后，治疗组pO₂高于对照组，pCO₂低于对照组（P＜0.05）。治疗后，两组CRP、NLR、EOS计数和血清PCT水平都低于组内治疗前（P＜0.05）；治疗组CRP、NLR、EOS计数和血清PCT水平都低于对照组（P＜0.05）。结论 儿童社区获得性肺炎应用金振口服液联合哌拉西林钠他唑巴坦钠治疗，疗效显著，安全性良好。该联合疗法能有效缓解症状，改善血气指标，减轻炎症反应，为儿童社区获得性肺炎的治疗提供了较佳选择。

Objective To investigate the clinical efficacy of Jinzhen Oral Liquid combined with piperacillin sodium and tazobactam sodium in treatment of community-acquired pneumonia in children. Methods A total of 86 children with community-acquired pneumonia who were treated in Xiaolan People’s Hospital of Zhongshan from January 2022 to November 2024 were selected and divided into control group and treatment group according to random number table method, with 43 cases in each group. The children in control group were treated with piperacillin sodium and tazobactam sodium for injection, 2.25 g each time. After being fully dissolved in the diluent, it was added to 100 mL of the injection solution for intravenous drip infusion, ≥ 30 minutes each time, 3 times daily. The children in treatment group took Jinzhen Oral Liquid orally on the basis of control group, 5 mL each time, 3 times daily. The treatment courses of both groups were 7 d. The clinical efficacy and improvement time of related symptoms were observed. The blood gas indexes [arterial partial pressure of oxygen (pO₂), arterial partial pressure of carbon dioxide (pCO₂)] and inflammatory markers [C-reactive protein (CRP), neutrophil lymphocyte ratio (NLR), eosinophil (EOS) count and serum procalcitonin (PCT)] levels before and after treatment were compared between two groups. Results After treatment, the total effective rate of treatment group was 97.67%, significantly higher than that of control group (86.05%, P < 0.05). After the treatment, the improvement times of shortness of breath, cough, fever, phlegm rumbling, and pulmonary rales in treatment group were significantly shorter than those in control group (P < 0.05). After treatment, pO₂ in both groups increased significantly, but pCO₂ decreased significantly (P < 0.05). After treatment, the pO₂ in the treatment group was higher than that in control group, and the pCO₂ was lower than that in control group (P < 0.05). After treatment, the level of CRP, NLR, EOS, and serum PCT in both groups were lower than those before treatment within the same groups (P < 0.05). The level of CRP, NLR, EOS, and serum PCT in treatment group were all lower than those in control group (P < 0.05). Conclusion Jinzhen Oral Liquid combined with piperacillin sodium and tazobactam sodium is effective and safe in treatment of community-acquired pneumonia in children. The combination therapy can effectively relieve symptoms, improve blood gas indexes, reduce inflammatory reaction, and provide a better choice for the treatment of community-acquired pneumonia in children.

R974